BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. Clin Dermatol 2020;38:384-96. [PMID: 32563354 DOI: 10.1016/j.clindermatol.2019.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yoo DS, Lee JH, Kim SC, Kim JH. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Br J Dermatol 2021;185:210-2. [PMID: 33657641 DOI: 10.1111/bjd.19890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Watson N, Carrozzo M, Hampton P. A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease. J Oral Pathol Med 2021;50:92-7. [PMID: 33184901 DOI: 10.1111/jop.13123] [Reference Citation Analysis]